Male hypoactive sexual desire disorder: paper guide
Thirteen prescribed sections over a nine-page minimum — and several of them, prevention and parenting skills among them, have almost no literature for this particular disorder. Handling that honestly is the assignment.
Editorial process
Last reviewed · August 5, 2026
Why this disorder does not fit the required section list
The brief gives you a fixed list of thirteen sections and a nine-page minimum, which makes this look like a filling-in exercise. It is not, and the reason is worth seeing early: the section list is a generic template the instructor applies across disorders, and this disorder does not fit all of it.
Work through the list and the mismatch is obvious. Criteria per the DSM-5, causes, symptoms and signs, treatment, prognosis, evidence-based therapies — all well supported for male hypoactive sexual desire disorder. But preventions, environmental causes, and above all parenting skills to help the individuals are headings built for childhood and developmental conditions. There is no meaningful literature on parenting skills for an adult sexual desire disorder, and a paper that invents some will be inventing it.
So the real skill being tested is what you do about that, and there is a right answer. Address every required section, because the list functions as a grading checklist and a missing heading loses marks mechanically. But where the evidence is thin, say that it is thin and say why, then give the nearest defensible content: for parenting, the family-of-origin and attachment literature on how early messages about sexuality shape adult desire; for prevention, the modifiable contributors — relationship factors, medication side effects, substance use, untreated depression — rather than a primary-prevention programme that does not exist. Naming an evidence gap and reasoning to the closest legitimate material is graduate-level behaviour. Padding the section with confident invention is the failure this paper is most likely to produce.
On content, four things are routinely got wrong and each is checkable. First, low desire is not the disorder: the DSM-5 requires that deficient or absent sexual thoughts, fantasies and desire persist for at least six months and cause marked distress, and that it is not better explained by another mental disorder, a medication or another medical condition. A paper describing low desire without the duration and distress thresholds has described a symptom, not a diagnosis. Second, different types means the DSM specifiers — lifelong versus acquired, generalized versus situational, with a severity rating — not a folk taxonomy you devise. Third, there is no FDA-approved pharmacotherapy for hypoactive sexual desire disorder in men; flibanserin and bremelanotide are approved for premenopausal women, and attributing them to men is a factual error that a marker in this field will catch immediately. Fourth, testosterone is indicated for confirmed hypogonadism diagnosed on unequivocally and consistently low morning serum testosterone — not as a treatment for low desire in eugonadal men, and the evidence that it lifts desire is mixed even where it is indicated.
One detail will lift the history and why the name sections above a Wikipedia summary. In DSM-5 the male and female diagnoses were deliberately separated: female hypoactive sexual desire disorder was merged with arousal difficulties into Female Sexual Interest/Arousal Disorder, while the male diagnosis was retained as a desire disorder in its own right. That asymmetry was argued over in the literature before DSM-5 was published, on the question of whether desire and arousal can be reliably distinguished in men at all. Reporting that debate answers 'why the name' as a history of a contested decision rather than an etymology.
Finally, do the arithmetic. Thirteen sections across nine pages of double-spaced text is roughly two-thirds of a page each. Sections with real literature deserve more and the thin ones deserve a short, honest paragraph — but every heading must appear.
Likely learning objectives
Inferred from the brief — check these against your own rubric.
- 01Apply the full DSM-5 diagnostic threshold — deficient desire, at least six months, marked distress, and exclusion of other causes — rather than describing low desire as though it were the diagnosis.
- 02Use the DSM specifiers as the disorder's 'types': lifelong versus acquired, generalized versus situational, with severity, instead of devising an informal taxonomy.
- 03Distinguish approved from off-label treatment accurately, recognising that no pharmacotherapy is FDA-approved for this disorder in men and that testosterone is indicated only for confirmed hypogonadism.
- 04Likely assessed on whether every prescribed section appears, since the brief supplies an explicit list that functions as a grading checklist.
- 05Tends to be rewarded when a section with a thin evidence base is identified as thin and reasoned to the nearest defensible literature, rather than filled with invented content.
Read the full question
Review every instruction before using the planning guidance that follows.
Every section and format rule the brief specifies
- 01A minimum of nine pages of content, plus a reference page as the last page.
- 02First page: name and last name, institution name, course number, professor name and due date, positioned in the middle of the page.
- 03APA formatted paper with 1-inch margins, Times New Roman 12pt, double-spaced, with page numbers.
- 04The prescribed sections, in the brief's own order: why the name of the disorder / concept or definition; DSM-5 diagnostic criteria; history; causes; symptoms and signs; different types; preventions; environmental causes; treatment plans with short-term and long-term goals; prognosis; tips or suggestions on how to overcome the disorder; parenting skills to help the individuals; and evidence-based therapies for the disorder.
- 05Proofreading is explicitly graded: the brief warns that reliance on spell-check alone and numerous errors will be penalised, and recommends reading the paper aloud before submission.
- 06The brief also warns against compressing or padding — small type, narrow margins, single spacing, large type, triple spacing and altered kerning are all called out, so let the paper run over rather than manipulate layout.
Mapping thirteen required sections across nine pages
Definition and why the disorder carries this name
Define the disorder and explain the naming as the outcome of a contested DSM-5 decision — the male diagnosis retained as a desire disorder while the female equivalent merged into a combined interest/arousal category.
DSM-5 diagnostic criteria in full
State every criterion: deficient or absent sexual thoughts, fantasies and desire; the minimum six-month duration; marked distress; and exclusion of another mental disorder, substance, medication or medical condition as a better explanation.
History of the diagnosis
Trace the diagnosis through the DSM editions and the pre-DSM-5 debate about whether desire and arousal are separable in men, citing the argument rather than only its outcome.
Causes, environmental contributors, and signs
Cover biological contributors (hypogonadism, hyperprolactinaemia, thyroid dysfunction), psychological ones (depression, anxiety), relational and sociocultural factors, and medication effects. Fold the brief's 'environmental causes' heading in here explicitly, then present symptoms and signs.
Different types — the DSM specifiers
Present lifelong versus acquired, generalized versus situational, and the severity rating, explaining what each distinction changes about assessment and likely management.
Prevention — and an honest account of its limits
Address the required heading by covering modifiable contributors: relationship quality, substance use, medication review, and treatment of depression. State plainly that primary prevention of this disorder is not an established literature.
Treatment plans with short- and long-term goals, and evidence-based therapies
Set out assessment-led management: correct reversible causes, treat hypogonadism where confirmed on repeat morning testosterone, and use cognitive-behavioural, mindfulness-based and couple-focused approaches. State that no pharmacotherapy is FDA-approved for men. Split goals into short-term and long-term as the brief requires.
Prognosis, self-management tips, and the family-of-origin section
Give prognosis by subtype and by whether a reversible cause was found. Provide practical suggestions. For the required 'parenting skills' heading, reason to the nearest defensible literature — family-of-origin and early messages about sexuality shaping adult desire — and say why the heading fits this disorder poorly.
Where the DSM-5 criteria and treatment evidence live
Recommended databases
- PubMed
- PsycINFO
- The Journal of Sexual Medicine
- European Association of Urology Guidelines
- Endocrine Society Clinical Practice Guidelines
Search sequence
- 1.Start with the current EAU sexual and reproductive health guideline chapter, which gives you definition, prevalence, assessment and management in one authoritative place and anchors the rest of the paper.
- 2.Search the DSM-5 criteria against a clinical reference rather than a consumer health site, and cite the manual itself for the criteria wherever your library provides access.
- 3.For the history and naming sections, search the pre-DSM-5 debate directly — the argument about whether desire and arousal are separable in men is a published literature, not background.
- 4.For treatment, search each modality separately and record its approval status; confirm which agents are approved for women only before writing anything about pharmacotherapy.
- 5.For the prevention and parenting sections, search deliberately and record what you do not find — that null result is the evidence for the honest statement those sections need.
Reference shortlist
These are authoritative starting points, not a ready-made bibliography. A qualified reviewer must confirm that each source fits the assignment and supports the claim beside which it is cited.
Nothing here is cleared for citation until you have read it.
- 01
Low Sexual Desire and Male Hypoactive Sexual Desire Disorder
European Association of Urology, Sexual and Reproductive Health Guidelines · 2026
The current guideline chapter, and the single most efficient source for definition, prevalence (a German survey of 12,646 men reporting 4.7%), assessment including the Sexual Desire Inventory and endocrine workup, and cause-directed management. Use it as the backbone for the criteria, causes and treatment sections.
- 02
The DSM Diagnostic Criteria for Hypoactive Sexual Desire Disorder in Men
The Journal of Sexual Medicine, 7(6), 2015-2030 · 2010
The pre-DSM-5 review that set out the options for the male diagnosis and named the unresolved question of whether desire and arousal can be reliably differentiated in men. This is the source for the history and 'why the name' sections. Note it predates DSM-5, so cite it as the argument that preceded the decision, not as current criteria.
- 03
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline
Journal of Clinical Endocrinology & Metabolism, 103(5), 1715-1744 · 2018
The authority for the testosterone boundary: diagnose hypogonadism only with consistent symptoms plus unequivocally and consistently low fasting morning serum testosterone, confirmed on repeat testing. Cite it to keep the treatment section from presenting testosterone as a general remedy for low desire.
- 04
Male Hypoactive Sexual Desire Disorder
PsychDB · 2021
A clinical quick-reference for the criteria structure and the specifiers — lifelong versus acquired, generalized versus situational, and severity — useful for organising the 'different types' section. It is a summary resource, not a primary source: use it to structure and verify against the manual itself.
Checking the paper against the brief's checklist
Common mistakes
- Describing low sexual desire without applying the diagnostic thresholds. The DSM-5 requires at least six months and marked distress, and without both you have described a symptom rather than a disorder.
- Attributing flibanserin or bremelanotide to men. Both are approved for premenopausal women with hypoactive sexual desire disorder, and no pharmacotherapy is FDA-approved for the disorder in men.
- Presenting testosterone as a treatment for low desire generally. It is indicated for confirmed hypogonadism on repeat morning testing, and the evidence that it improves desire is mixed even then.
- Inventing content for the parenting-skills section. There is no parenting-skills literature for an adult sexual desire disorder, and fabricating one is a worse outcome than naming the gap and reasoning to family-of-origin research.
- Skipping a prescribed section because it does not fit. The list operates as a grading checklist and a missing heading loses marks whether or not the omission was justified.
- Inventing an informal taxonomy for 'different types' when the DSM already supplies the specifiers — lifelong versus acquired, generalized versus situational, and severity.
- Failing to distinguish the disorder from low desire that is fully explained by a medication, a medical condition, or another mental disorder, which the criteria explicitly exclude.
- Merging short-term and long-term goals into a single treatment list when the brief asks for both separately.
- Manipulating layout to reach nine pages. The brief specifically calls out compressed type, altered margins, spacing and kerning, and says it is better to run over than to compress.
Submission checklist
- Every one of the prescribed sections appears under its own heading, in the brief's order.
- The DSM-5 criteria include the six-month duration, the marked distress requirement, and the exclusion criteria.
- 'Different types' presents the DSM specifiers with their clinical implications.
- No treatment is described as FDA-approved for men, and any agent approved for women is identified as such.
- Testosterone is tied to confirmed hypogonadism rather than to low desire in general.
- The prevention and parenting sections state the limits of the evidence explicitly and offer the nearest defensible material.
- Treatment goals are split into short-term and long-term.
- The paper reaches nine pages of content without layout manipulation, with the reference page last.
- The first page carries name, institution, course number, professor name and due date, centred as specified.
- APA formatting throughout: 1-inch margins, Times New Roman 12pt, double-spaced, page numbers.
- The paper has been proofread on screen and aloud, not only spell-checked.
Use this guide to plan and review your own work. Follow your institution's rules and read our academic-integrity policy.
Written by
Hannah Prescott
MSN, RN
Medical-surgical nursing, pharmacology and NCLEX preparation
Hannah is a registered nurse with over 15 years of clinical and educational experience in medical-surgical nursing. She writes on NCLEX preparation, patient care fundamentals, pharmacology and evidence-based practice.
Reviewed by
Rachel Stokes
DNP, PMHNP-BC
Psychiatric disorders, therapeutic communication and psychopharmacology
Rachel is a board-certified Psychiatric-Mental Health Nurse Practitioner with 14 years providing mental health care across inpatient and outpatient settings. She reviews psychiatric disorders, therapeutic communication, psychopharmacology and behavioral health nursing content.